JW Therapeutics filed with Hong Kong Exchanges and Settlements Limited on 4 January 2024 with Hong Kong Trading and Settlement Holdings Limited on 31 December 2023. The report shows that the company's regulated/registered share capital remained unchanged, with 5,000,000,000 shares outstanding at the end of last month and the end of this month, with a face value of $0.00001 per share and a total regulated/registered share capital of $50,000. In terms of stock options, under the Initial Public Offering Incentive Plan adopted on 4 September 2019 and the Initial Public Offering Incentive Plan adopted on 14 October 2020, share options were exercised and expired this month, but the number of options outstanding at the end of the month was not significantly changed. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

JW Therapeutics filed with Hong Kong Exchanges and Settlements Limited on 4 January 2024 with Hong Kong Trading and Settlement Holdings Limited on 31 December 2023. The report shows that the company's regulated/registered share capital remained unchanged, with 5,000,000,000 shares outstanding at the end of last month and the end of this month, with a face value of $0.00001 per share and a total regulated/registered share capital of $50,000. In terms of stock options, under the Initial Public Offering Incentive Plan adopted on 4 September 2019 and the Initial Public Offering Incentive Plan adopted on 14 October 2020, share options were exercised and expired this month, but the number of options outstanding at the end of the month was not significantly changed. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.